DACS
VRTX icon

Dymon Asia Capital (Singapore)’s Vertex Pharmaceuticals VRTX Stock Holding History

Dymon Asia Capital (Singapore)’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.75M Buy
+5,546
New +$2.46M 0.12% 102
2026
Q1 		– Sell
-4,200
Closed -$1.9M – 327
2025
Q4 		$1.9M Buy
+4,200
New +$1.81M 0.19% 107
2021
Q1 		– Sell
-2,100
Closed -$496K – 187
2020
Q4 		$496K Buy
+2,100
New +$482K 0.11% 85

Other funds holding VRTX

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.94% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Dymon Asia Capital (Singapore)'s VRTX Position: Q2 2026 in Review

Dymon Asia Capital (Singapore) opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 5,546 shares worth $2.75M. The stake represents 0.12% of the portfolio and ranks #102 among its holdings. This is a return to the name: Dymon Asia Capital (Singapore) previously reported a position in VRTX as recently as Q4 2025.

Dymon Asia Capital (Singapore) first reported a position in VRTX in Q4 2020 and has held it in 3 quarters since. 827 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Dymon Asia Capital (Singapore) held 5,546 shares of Vertex Pharmaceuticals worth $2.75M as of Q2 2026.
  • Vertex Pharmaceuticals was a new Dymon Asia Capital (Singapore) position in Q2 2026.
  • Vertex Pharmaceuticals made up 0.12% of Dymon Asia Capital (Singapore)'s portfolio in Q2 2026, its #102 holding.
  • Dymon Asia Capital (Singapore) first reported a position in Vertex Pharmaceuticals in Q4 2020 and has held it in 3 quarters since.
  • 827 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Dymon Asia Capital (Singapore)'s 13F filing for Q2 2026, filed 23 Jul 2026.